Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337698 · ClinicalTrials.gov registry record · Phase 1
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 314
- Enrollment target
NCT03337698 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 314 participants.
The verdict
NCT03337698, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 314 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).
Interventions
- DRUG Docetaxel
- DRUG Atezolizumab
- DRUG Cobimetinib
- DRUG RO6958688
- DRUG CPI-444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03337698
The ClinicalTrials.gov registry entry for NCT03337698 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT03337698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03337698 about?
NCT03337698 is a clinical study titled "A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)". This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expres...
What is the current status of trial NCT03337698?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 314 participants. The study started on 2017-12-27. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT03337698?
The interventions under investigation include: Docetaxel (DRUG), Atezolizumab (DRUG), Cobimetinib (DRUG), RO6958688 (DRUG), CPI-444 (DRUG).
Who is sponsoring clinical trial NCT03337698?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.